Robert  Coffin net worth and biography

Robert Coffin Biography and Net Worth

Insider of Replimune Group
Robert Coffin is Founder, President and Chief Research & Development Officer of Replimune. Previously he was Founder & CTO of BioVex Inc, a spin out from his research group at University College London in 1999. BioVex was acquired by Amgen in 2011 where Rob was VP Global Development until 2013, before co-founding Replimune in 2015. Rob was awarded a PhD in virology from Imperial College London prior to his move to University College London in 1991.

What is Robert Coffin's net worth?

The estimated net worth of Robert Coffin is at least $14.76 million as of June 28th, 2021. Dr. Coffin owns 1,806,320 shares of Replimune Group stock worth more than $14,757,634 as of March 28th. This net worth evaluation does not reflect any other assets that Dr. Coffin may own. Additionally, Dr. Coffin receives a salary of $785,890.00 as Insider at Replimune Group. Learn More about Robert Coffin's net worth.

How old is Robert Coffin?

Dr. Coffin is currently 59 years old. There are 9 older executives and no younger executives at Replimune Group. The oldest executive at Replimune Group is Dr. Colin A. Love Ph.D., Chief Operating Officer, who is 66 years old. Learn More on Robert Coffin's age.

What is Robert Coffin's salary?

As the Insider of Replimune Group, Inc., Dr. Coffin earns $785,890.00 per year. The highest earning executive at Replimune Group is Mr. Philip Astley-Sparke F.S.A., CEO & Director, who commands a salary of $1,070,000.00 per year. Learn More on Robert Coffin's salary.

How do I contact Robert Coffin?

The corporate mailing address for Dr. Coffin and other Replimune Group executives is 500 Unicorn Park, WOBURN MA, 01801. Replimune Group can also be reached via phone at (781) 222-9600 and via email at [email protected]. Learn More on Robert Coffin's contact information.

Has Robert Coffin been buying or selling shares of Replimune Group?

Robert Coffin has not been actively trading shares of Replimune Group in the last ninety days. Most recently, Robert Coffin sold 7,810 shares of the business's stock in a transaction on Friday, July 2nd. The shares were sold at an average price of $40.04, for a transaction totalling $312,712.40. Learn More on Robert Coffin's trading history.

Who are Replimune Group's active insiders?

Replimune Group's insider roster includes Robert Coffin (Insider), Pamela Esposito (Insider), and Colin Love (COO). Learn More on Replimune Group's active insiders.

Are insiders buying or selling shares of Replimune Group?

During the last year, insiders at the sold shares 10 times. They sold a total of 121,134 shares worth more than $2,331,903.29. The most recent insider tranaction occured on November, 16th when insider Konstantinos Xynos sold 7,313 shares worth more than $79,857.96. Insiders at Replimune Group own 20.6% of the company. Learn More about insider trades at Replimune Group.

Information on this page was last updated on 11/16/2023.

Robert Coffin Insider Trading History at Replimune Group

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/2/2021Sell7,810$40.04$312,712.40View SEC Filing Icon  
6/28/2021Sell14,663$40.04$587,106.521,806,320View SEC Filing Icon  
1/22/2021Sell60,000$44.43$2,665,800.001,773,921View SEC Filing Icon  
12/22/2020Sell220,000$40.04$8,808,800.00View SEC Filing Icon  
7/9/2020Sell169,750$22.13$3,756,567.502,048,368View SEC Filing Icon  
11/6/2019Sell48,500$16.92$820,620.00
10/31/2019Sell24,250$17.02$412,735.00
9/23/2019Sell24,250$17.05$413,462.50
See Full Table

Robert Coffin Buying and Selling Activity at Replimune Group

This chart shows Robert Coffin's buying and selling at Replimune Group by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Replimune Group Company Overview

Replimune Group logo
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Read More

Today's Range

Now: $8.17
Low: $8.04
High: $8.46

50 Day Range

MA: $8.10
Low: $6.87
High: $9.03

2 Week Range

Now: $8.17
Low: $5.89
High: $24.81

Volume

1,098,878 shs

Average Volume

1,474,880 shs

Market Capitalization

$501.56 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22